missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Gibco™ ExpiFectamine™ 293 Transfection Kit
Designed for transient transfection of high density cultures of HEK (human embryonic kidney) 293 cells.
Brand: Gibco™ A14524
1067.58 EUR valid until 2024-12-31
Use promo code "21651" to get your promotional price.
This item is not returnable.
View return policy
Description
The ExpiFectamine™ 293 Transfection Kit is a core component of the Expi293™ Expression System. It is designed for transient transfection of high density cultures of HEK (human embryonic kidney) 293 cells. The high-efficiency, cationic, lipid-based transfection reagent and transfection enhancers are designed to power the highest possible level of protein expression from Expi293F™ cells cultured in Expi293™ Expression Medium
- Designed specifically for transfection of high density suspension cell culture, with matching transfection enhancers that boost transfection performance and protein expression
- Achieves protein yields 2- to 10-fold higher than other transfection reagents used on high density 293 cell cultures
- Employs the same transient expression protocols typically used in current low-density 293 suspension culture systems to easily switch from low density systems to the high yield, high density Expi293™ Expression System
- Provides robust and reproducible transfection results, giving users greater confidence in their results
- Scale transfections for culture volumes of less than 1 mL to greater than 10 liters, while maintaining equivalent volumetric protein yields
The ExpiFectamine™ 293 Transfection Kit is specifically designed to work with Expi293F™ cells in the Expi293™ Expression System. The transfection kit consists of the cationic lipid-based ExpiFectamine™ 293 Reagent and ExpiFectamine™ 293 Transfection Enhancers 1 and 2. The enhancers are added 18 to 22 hours post-transfection to boost transfection, cell viability, and protein expression. The protocol for use of ExpiFectamine™ 293 Transfection components is very similar to transfection protocols for other transient expression reagents, such as 293fectin™ and FreeStyle™ MAX.
Specifications
| Expi293F™ | |
| 2.7 mL (3 x 0.9 mL) ExpiFectamine™ 293 Reagent 5 mL ExpiFectamine™ 293 Transfection Enhancer 1 50 mL ExpiFectamine™ 293 Transfection Enhancer 2 Sufficient for transfection of 1 L of culture Store at 2°C to 8°C |
|
| Plasmid DNA | |
| Transfection | |
| Transfection Kit | |
| For 1 L of culture |
| Animal Origin-Free, Chemically Defined, Protein-Free, Serum-Free | |
| Established Cell Lines | |
| Lipid-based Transfection | |
| ExpiFectamine™ | |
| Cell Culture Grade | |
| No |
Safety and Handling
Product Identifier
Signal Word
Hazard Category
Hazard Statement
Precautionary Statement
Supplemental information
- ExpiFectamine 293 Transfection Kit
Signal Word
- Warning
Hazard Category
- Acute toxicity Category 4
- Serious eye damage/eye irritation Category 2
- Skin corrosion/irritation Category 2
- Specific target organ toxicity Category 3
Hazard Statement
- H302-Harmful if swallowed.
- H312-Harmful in contact with skin.
- H315-Causes skin irritation.
- H319-Causes serious eye irritation.
- H332-Harmful if inhaled.
- H335-May cause respiratory irritation.
Precautionary Statement
- P261-Avoid breathing dust/fume/gas/mist/vapours/spray.
- P280-Wear protective gloves/protective clothing/eye protection/face protection.
- P301+P312-IF SWALLOWED: Call a POISON CENTER or doctor/physician/ if you feel unwell.
- P302+P352-IF ON SKIN: Wash with plenty of water/soap.
- P304+P340-IF INHALED: Remove person to fresh air and keep comfortable for breathing.
- P305+P351+P338-IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
Supplemental information
- MIXTURE LIST-Contains : 3-Fluoro-4-nitrophenol
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
For Research Use Only. Not for use in diagnostic procedures.
Spot an opportunity for improvement?Share a Content Correction